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Rifampicin Inhibits -Synuclein Fibrillation
and Disaggregates Fibrils
establish potential inhibitors of -synuclein fibrillation
[21]. Fifteen of 169 compounds screened inhibited fibril
formation of -synuclein. All but one of the inhibitors
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University of California, Santa Cruz were catecholamines, including dopamine and L-dopa,
norepinephrine, and epinephrine. It was concluded thatSanta Cruz, California 95064
the inhibitory activity of dopamine depended on its oxi-
dative ligation to -synuclein [21].
Epidemiological studies have indicated that leprosySummary
patients had significantly lower probability of senile de-
mentia development if they had been under antileprosyThe aggregation of -synuclein in dopaminergic neu-
treatment with dapsone or rifampicin (Figure 1) androns of the substantia nigra is a critical step in the
closely related drugs for the preceding several yearspathogenesis of Parkinson’s disease. We show that
[22, 23]. For example, it has been shown that the overallthe antibiotic rifampicin inhibited -synuclein fibril-
prevalence of senile dementia was 2.9% in 1410 patientslation and disaggregated existing fibrils in a concen-
who were continuously on antileprosy treatment, com-tration-dependent manner. Size-exclusion chroma-
pared with 6.25% in 1761 untreated patients [24]. Basedtography data indicated that rifampicin stabilized
on this observation, it has been suggested that some-synuclein as both a monomer and soluble oligomers
drugs being used for leprosy might prevent A aggrega-comprised of partially folded -synuclein. Experi-
tion, thus resulting in the absence of amyloid depositionments using aged samples of rifampicin indicated that
[25]. This hypothesis has been tested with two antilep-the most active species in inhibiting fibrillation and
rosy drugs, depasone and rifampicin, and it has beendisaggregating fibrils is an oxidation product of rifam-
found that rifampicin and its analogs, p-benzoquinonepicin, which was confirmed in experiments under an-
and hydroquinone, inhibited A1-40 or A1-42 aggrega-aerobic conditions. These results indicate that rifampi-
tion and neurotoxicity in vitro [25–27]. Similar rifampicincin-mediated inhibition of -synuclein fibrillation and
effects have been recently reported for human islet amy-disaggregation of fibrils involves preferential stabiliza-
loid polypeptide, amylin [26]. Rifampicin is a semisyn-tion of monomeric and soluble oligomeric forms, and
thetic derivative of the rifamycins, a class of antibioticsthat rifampicin potentially may have therapeutic appli-
that are fermentation products of Nocardia mediterraneication for Parkinson’s disease.
[28]. The common structure of rifamycins is a naphtho-
hydroquinone or naphthoquinone chromophore spanned
Introduction by an aliphatic chain. In addition to treatment for leprosy,
rifampicin is widely used in some countries for the treat-
Human -synuclein is a 140 residue, highly conserved ment of tuberculosis [29].
presynaptic protein that is abundant in various regions Observations that catecholamines inhibited fibril for-
of the brain [1, 2]. It is found as both a soluble cyto- mation of -synuclein [21, 30] and that rifampicin and
plasmic protein and associated with presynaptic vesi- related drugs prevented aggregation and neurotoxicity
cles, and it may play a role in synaptic release of neuro- of Apeptide and amylin [25–27] led us to investigate the
transmitters [1, 3]. Structurally, purified -synuclein is a effect of rifampicin on -synuclein aggregation in vitro.
natively unfolded protein at neutral pH [4–9]. Pathologi- Although the mechanism of rifampicin inhibition of fibril-
cally, Parkinson’s disease (PD) is characterized by the lation is unknown, it has been suggested that it may act
progressive loss of dopaminergic neurons from the sub- as a free radical scavenger. In the present study, we
stantia nigra region of the brain, with some surviving show that rifampicin can inhibit -synuclein fibrillation
nigral dopaminergic neurons containing cytosolic fila- and efficiently disaggregates preformed fibrils in a con-
mentous inclusions known as Lewy bodies (LBs) and centration-dependent manner. Subsequent analysis
Lewy neurites (LNs) [10]. -synuclein is a major fibrillar suggested that these effects result from the preferential
component of LBs and LNs [11, 12]. The aggregation stabilization of monomeric and soluble oligomeric forms
of -synuclein is thought to be a critical step in the of the protein by rifampicin or its derivatives. Thus, rifam-
pathogenesis of PD and several other neurodegenera- picin may potentially have therapeutic application for
tive disorders [13]. Recently, it has been suggested that Parkinson’s disease.
the precursors of fibrils, oligomers of -synuclein, might
be more toxic than fibrils [14, 15].
The mechanisms of in vivo -synuclein aggregation Results
and toxicity are not well understood. However, it has
been shown that many environmental factors, including Rifampicin Inhibits -Synuclein Fibrillation
heavy metals and pesticides, may facilitate the aggrega- in a Dose-Dependent Manner
tion process [16, 5, 17–20]. Recently, a commercially Thioflavin T (ThT) is a fluorescent dye, which interacts
available library of drug-like molecules was analyzed to with fibrils relatively specifically, and is widely used for
the detection of amyloid fibrils [31, 32]. We first exam-
ined the effect of rifampicin on the kinetics of fibrillation*Correspondence: enzyme@cats.ucsc.edu
Chemistry & Biology
1514
Figure 1. The Structure of Rifampicin, Its Naphthyl Core, and Qui-
none Form
The lower structures show the naphthyl core of rifampicin (left) and
the corresponding quinone form (right).
of -synuclein. As shown in Figure 2A, the fibrillation of
-synuclein is completely inhibited by 100 M rifampicin
as monitored by ThT. Confirmation that fibrillation was
inhibited by rifampicin was obtained by static light scat-
tering experiments (data not shown) and by measuring
the amount of insoluble material as a function of time
using the Lowry assay to determine the concentration
of protein in both supernatant and pellet (Figure 2B)
(aliquots were removed at various times during the incu-
bation and centrifuged, prior to the assays). In addition,
pellets and supernatants were analyzed using SDS
PAGE: the data (data not shown) indicate that most of
the protein (90%) was in the insoluble fraction in the
control experiment, whereas in the presence of rifampi-
cin most of the protein was in the soluble fraction, con-
firming that rifampicin inhibited aggregation. Figures 2B Figure 2. Rifampicin Inhibits -Synuclein Fibrillation
and 2C show that rifampicin inhibits the aggregation (A) Kinetics of fibril formation monitored by ThT fluorescence. Con-
of -synuclein in a concentration-dependent manner, trol (circles), with 50 M (triangles), and 100 M rifampicin (dia-
based on both ThT fluorescence and protein deposited, monds). Increasing concentrations of rifampicin lead to slower kinet-
ics of fibrillation and fewer fibrils.as measured by the Lowry assay. Near-maximal inhibi-
(B and C) Dose-dependent inhibition of -synuclein fibrillation bytion is obtained with 50 M rifampicin.
rifampicin. (B) shows that the amount of insoluble -synuclein de-In order to elucidate the molecular mechanism of ri-
creases with increasing rifampicin, as shown by the decreased ThT
fampicin inhibition of -synuclein aggregation, the time signal (black) and the amount of protein in the pellet (gray, measured
course of changes in the far-UV CD spectra of the solu- by the Lowry assay) at completion of the incubation compared to
ble fraction of the protein in the absence or in the pres- the value in the absence of rifampicin (100%). In (C), the final ThT
signal (a measure of the amount of fibrils) is shown as a functionence of 100 M rifampicin were studied. To this end,
of rifampicin concentration. The incubation conditions were 70 Maliquots of the incubation mixture were withdrawn at
-synuclein (pH 7.4), 100 mM NaCl, 37C.desired time points and spun at 14,000  g for 15 min
to remove insoluble material, and the supernatants were
subjected to far-UV CD analysis. Figure 3A shows that the vicinity of 198 nm and the absence of bands in the
210–230 nm region. However, the far-UV CD spectrumwithin the time interval from 0 and 24 hr in the absence
of rifampicin the far-UV CD spectrum of the soluble measured for the soluble fraction of -synuclein after
40 hr of incubation possessed features characteristic of-synuclein fraction was indicative of a substantially
unfolded protein. This was manifested by a minimum in a partially folded conformation. Figure 3A shows that
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Figure 4A compares size-exclusion chromatography
(SEC) profiles measured for the soluble fractions of
-synuclein incubated in the absence or presence of
100 M rifampicin. The position of the monomer peak
(Vel  18.5 ml, which corresponded to RS  35  2 A˚, a
value appropriate for natively unfolded -synuclein [33])
was identical in the presence or absence of rifampicin.
After 42 hr of incubation in the absence of rifampicin,
there was only a trace of monomer present in the super-
natant, whereas in the presence of 100 M rifampicin
a large amount of monomer and some oligomer were
observed in the solution. Thus, either a mixture of mono-
mer and oligomer are formed in the presence of rifampi-
cin, or the soluble oligomer(s) is not very stable and
mostly dissociated during the chromatographic pro-
cess. Regardless, the fact that the oligomers are present
in the HPLC eluant after 15 min on the column indicates
that the dissociation rate of the oligomers is quite slow.
In either case, the results indicate that rifampicin pre-
vents -synuclein from fibrillation and deposition.
The HPLC SEC data provide a number of additional
insights into the interaction of rifampicin with -synu-
clein. As shown in Figure 4B, monitoring the absorbance
at 480 nm, where only rifampicin absorbs, shows that
the soluble material after 24 or 48 hr of incubation con-
tains both monomeric and oligomeric -synuclein and
that, in both cases, rifampicin is tightly or covalently
bound to the protein.
Further confirmation that rifampicin inhibits -synu-
clein fibrillation comes from electron microscope (EM)Figure 3. Rifampicin Prevents Significant Conformational Change
images of amyloid fibrils formed from -synuclein inin -Synuclein
the absence and presence of 100 M rifampicin. In theFar-UV circular dichroism spectra as a function of time. (A) Spectra
absence of rifampicin (Figure 5A), long needle-like fibrilsof the supernatant in the absence of rifampicin, showing increasing
amounts of -structure with time; (B) in the presence of 100 M were observed with a diameter of 6–12 nm (the thicker
rifampicin. Spectra were taken at 0 hr (solid line), 16 hr (dotted line), fibrils appeared to arise from interaction of thinner ones).
24 hr (short dash), 40 hr (dash-dot-dot), 46 hr (long dash), 64 hr (dash- In the presence of rifampicin (Figure 5B), the amount of
dot), and 72 hr (medium dash). Conditions are described under fibrils formed was minimal, and it was difficult to find
Experimental Procedures, and the spectra are corrected for protein
fibrils on the grid. Fibrils that were observed to grow inconcentration and any contribution of rifampicin.
the presence of rifampicin appear essentially thinner and
considerably shorter that those grown in the absence of
the minimum in the vicinity of 200 nm decreased in the antibiotic.
intensity, whereas the negative intensity of the spectrum
around 220 nm increased, reflecting incubation-induced
formation of secondary structure. Previously, we have Effect of Rifampicin Oxidation
Aqueous solutions of rifampicin are unstable and breakshown that such structural changes may be due to the
formation of soluble oligomeric species comprised of down to 3-formyl rifampicin and rifampicin quinone (fa-
vored by acidic and basic conditions, respectively). Thispartially folded -synuclein [5, 20]. At 72 hr, after fibrilla-
tion was essentially complete, the soluble fraction of degradation can be readily monitored spectrophotomet-
rically around 480 nm [34]. Under the conditions used-synuclein showed a far-UV CD spectrum typical of a
 sheet protein, which we attribute to the presence of for -synuclein fibrillation (pH 7.5, 37C), we found the
rate of degradation of 100 M rifampicin to be biphasic,soluble oligomeric intermediates of -synuclein. It is
important to note that because the CD spectra are only i.e., biexponential, with observed rate constants of
0.84  0.06 and 0.067  0.007 hr	1, based on the de-of the soluble fractions of the reaction mixture, the actual
intensities of the far-UV CD spectra were decreased crease in absorbance at 483 nm. Thus, significant
amounts of degradation products will be present duringstarting from 46 hr, when significant fibrillation began.
In contrast, incubation of -synuclein with rifampicin the incubation. This was confirmed by ESI mass spec-
trometry; the major component having a molecular mass(100 M) for 46 hr was not accompanied by any signifi-
cant changes in the CD spectra (Figure 3B), indicating of 221.7 Da, corresponding to the naphthyl core of rifam-
picin. Other major products had molecular masses ofthe lack of change in the protein secondary structure.
Only after incubation for 64 hr were minor changes in 353, 383 (quinone), 441, 455, and 528 Da. In order to
determine whether rifampicin itself or its degradationthe far-UV CD spectrum observed, and the intensities
of the spectra did not decrease after incubation for 64 products were responsible for the inhibition of -synu-
clein fibrillation, we preincubated 100 M rifampicin forhr in the presence of the rifampicin.
Chemistry & Biology
1516
Figure 4. The Presence of Rifampicin Leads
to Stable -Synuclein Oligomers Containing
Rifampicin
Size-exclusion chromatography (SEC) pro-
files for the soluble fractions of -synuclein
(70M) incubated in the absence or presence
of 100 M rifampicin. The monomer elutes at
18.5 min and the oligomer at 14.5 min.
(A and B) Inhibition of fibrillation by rifampicin.
After 42 hr incubation in the absence of rifam-
picin (A) (solid line), there is just a trace of
monomer in the supernatant. However, in the
presence of 100 M rifampicin (dotted line),
both monomer and oligomer are observed.
(B) Monitoring at 480 nm, where only rifampi-
cin absorbs, shows that rifampicin is cova-
lently associated with the monomer and
oligomer (dotted line). A control of monomeric
-synuclein (dashed line) shows no signal at
480 nm.
(C and D) Disaggregation of-synuclein fibrils
(100 M) by rifampicin (100 M) leads to
oligomer formation (dashed lines); the increased intensity of the oligomers at 275 nm (relative to 215 nm) reflect contributions from covalently
bound rifampicin. The dotted lines are for -synuclein monomers, and the solid black line is for the supernatant from incubation in the absence
of rifampicin. Incubation conditions were pH 7.4, 100 mM NaCl, 37C.
24 or 48 hr prior to initiating fibrillation. As shown in dation of rifampicin in the presence of oxygen (under
nonanaerobic conditions), there will always be someFigure 6A, under anaerobic conditions, in which the oxi-
dative breakdown of rifampicin is inhibited, the inhibitory oxidative products present, and these will increase at
longer incubation times. Interestingly, in the presenceeffect of rifampicin was much reduced, indicating that
it is one of the oxidative products that is responsible of antioxidants such as glutathione and ascorbic acid,
which would be anticipated to minimize the oxidationfor most of the inhibition. Given the relatively fast degra-
Figure 5. Rifampicin Inhibits -Synuclein Fi-
bril Formation and Disaggregates Existing Fi-
brils
TEM images of -synuclein fibrils (A) after
incubation of 35 M -synuclein (pH 7.4),
37C, for 72 hr. In the presence of 100 M
rifampicin (B), very few fibrils are observed. The
inset shows a close-up of an annular oligomeric
intermediate (outer diameter 40–50 nm): both
spherical and annular intermediates were ob-
served, as well as very short fibrils. Similarly,
incubation of -synuclein fibrils (56 M,
grown over 96 hr) for 68 hr in the absence (C)
and presence of 100M rifampicin (D) demon-
strates rifampicin-induced dissociation of fi-
brils. The scale bar is 160 nm for (A) and (B)
and 2 m in (C) and (D).
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Figure 6. Oxidized Rifampicin Is More Effective Than Rifampicin in Fibril Inhibition and Disaggregation
(A and B) Fibrillation of -synuclein monitored by ThT. (A) -synuclein incubated under anaerobic conditions: control (filled circles), 100 M
freshly prepared rifampicin (triangles), 100 M 24 hr aged rifampicin (open circles). (B) Glutathione and ascorbic acid (AA) prevent oxidation
of rifampicin and thereby prevent rifampicin inhibition of -synuclein fibrillation. Control (circles), 50 M rifampicin plus 400 mM AA (triangles),
or GSH (diamonds), 50 M rifampicin (inverted triangles). The decreased ThT signal at long times in the presence of GSH or AA is attributed
to rifampicin-induced disaggregation of fibrils (see main text). Conditions were 30 M -synuclein, pH 7.4, 100 mM NaCl, 37C.
(C–E) Rifampicin disaggregates -synuclein fibrils. (C) Fibrils of -synuclein (0.8 mg/ml) were incubated at pH 7.4, 37C in the absence (circles)
and presence (squares) of 100 M rifampicin. (D) Oxidized rifampicin (preincubated for 24 hr) (open circles) is more effective at disaggregating
-synuclein fibrils compared to fresh rifampicin (filled circles). (E) The addition of rifampicin (100 M, triangles) after 24 hr of -synuclein
incubation leads to disaggregation of fibrils. In each case, the reaction was monitored by ThT fluorescence, and the conditions were pH 7.4,
37C. The ThT signal magnitudes in different panels vary because samples were measured with two different systems (see Experimental
Procedures).
of rifampicin, the addition of rifampicin to -synuclein crease. This is most readily explained by assuming that
some oxidation of rifampicin occurred, but at a slow rate,incubations led to minimal inhibition (Figure 6B). We
interpret this to mean that the antioxidants resulted in and the resulting oxidized rifampicin inhibited further
fibrillation and disaggregated existing fibrils (see below).maintenance of a high concentration of nonoxidized ri-
fampicin, and this had little inhibitory effect. At longer ESI mass spectrometry was used to examine -synu-
clein after incubation in the presence and absence oftime periods of incubation with both rifampicin and glu-
tathione or ascorbic acid, the ThT signal began to de- rifampicin: no detectable differences were observed,
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suggesting that the soluble -synuclein (monomer and
oligomers) had not been covalently modified by rifampi-
cin or its degradation products, at least under the experi-
mental conditions used. However, if a covalent imine
adduct had formed between oxidized rifampicin and the
lysine side chains of -synuclein, it is possible that it
would have been hydrolyzed under the acidic conditions
used for preparing the MS sample.
Rifampicin Dissolves -Synuclein Fibrils
We next addressed the question of whether rifampicin
could disaggregate existing fibrils of -synuclein. Figure
6C shows that coincubation of -synuclein fibrils with
100 M rifampicin is accompanied by a large decrease
in ThT signal as well as a substantial decrease in the Figure 7. Rifampicin-Induced Disaggregation of -Synuclein Fibrils
Leads to Conformational Changesamount of insoluble material (based on Lowry assays;
data not shown). Thus, rifampicin can dissolve pre- Far-UV circular dichroism spectra of -synuclein: control, mono-
meric -synuclein (solid line); supernatant after incubation offormed -synuclein fibrils. The kinetics of rifampicin-
-synuclein fibrils with 100 M rifampicin (dotted); supernatant afterinduced disaggregation of -synuclein fibrils are bipha-
incubation of -synuclein with rifampicin (dash-dot-dot); and forsic, with the half-life for the faster, main process being
comparison, the supernatant after incubation of -synuclein in the
1 hr under the experimental conditions used. If the absence of rifampicin (dashed). Conditions are described under
rifampicin was allowed to undergo oxidative degrada- Experimental Procedures.
tion prior to addition to the fibrils, the kinetics of disag-
gregation were significantly faster, indicating that both
Discussionbreakdown products and intact rifampicin are active
in disaggregation (Figure 6D). The addition of 50 M
The aggregation of -synuclein is a key factor in therifampicin to -synuclein that had been incubated for
development of Parkinson’s disease and related-synu-24 hr led to a decrease in the ThT signal, consistent
cleinopathies [13, 35]. Consequently, molecules that in-with the disaggregation of fibrils (Figure 6E).
hibit fibrillation or disaggregate fibrils of -synucleinFurther confirmation that rifampicin dissolves -synu-
may lead to therapies to prevent or control Parkinson’sclein fibrils and leads to the formation of soluble oligo-
disease as well as to a better understanding of the pro-mers was obtained from SEC HPLC experiments. When
cess. Substantial evidence suggests that factors that
-synuclein fibrils were incubated at 37C in buffer (pH
destabilize the proteins involved in deposition diseases
7.4) and then centrifuged, the supernatant contained
lead to the population of partially folded intermediates,
virtually no soluble protein (Figures 4C and 4D). How-
which are critical species in the aggregation process
ever, if the fibrils were incubated with 100M rifampicin,
[36]. In contrast, for natively unfolded proteins, such as
the HPLC trace showed only soluble oligomers. Further-
-synuclein, it is factors that lead to partial folding that
more, the intensity of the peak at 275 nm compared are critical in aggregation [9]. The underlying kinetic
to 215 nm indicated that rifampicin was bound to the basis of fibrillation is consistent with a nucleated poly-
oligomers. merization and can be considered to consist of two
The results of EM analysis also demonstrated the ri- components, a lag phase leading to formation of the
fampicin-induced dissociation of preformed-synuclein nucleus, followed by rapid formation of fibrils, which
fibrils (Figure 5) as the amount of fibrillar material ad- grow through exponential elongation and possible sub-
sorbed on the grid decreased drastically after 68 hr sequent lateral interactions. Several recent observations
incubation of -synuclein fibrils in the presence of 100 suggest that oligomeric intermediates (sometimes called
M rifampicin (compare Figures 5C and 5D). protofibrils) present during aggregation may be more cyto-
We used circular dichroism to investigate the second- toxic then fibrils themselves [37–43]. The minimum ki-
ary structure of -synuclein in the soluble oligomers netic scheme for -synuclein aggregation/fibrillation in-
formed after disaggregation in the presence of rifampi- volves the initial formation of a critical partially folded
cin. Figure 7 compares the far-UV CD spectra of natively intermediate that undergoes partitioning either to fibrils,
unfolded-synuclein and the soluble fractions extracted soluble oligomers, or amorphous aggregates.
from incubation of -synuclein fibrils in the absence or The data presented here indicate that rifampicin, in
in the presence of rifampicin. Both spectra correspond- the 1–10 M concentration range, leads to inhibition
ing to the soluble fractions had shapes typical of -struc- of -synuclein fibril formation. Furthermore, the results
tural proteins. The CD analysis clearly demonstrates that demonstrate that existing fibrils are disaggregated by
the conformation of -synuclein in the soluble species similar concentrations of rifampicin. In both cases, inhi-
resulting from rifampicin-induced dissociation of fibrils bition and disaggregation, the end product is a mixture
was predominantly -structure. Consequently, the SEC of a large soluble oligomer of -synuclein, with substan-
HPLC and far-UV CD data indicate that the rifampicin- tial  sheet structure, and monomer. In addition, our
disaggregated fibrils were stabilized in the form of large observations reveal that an oxidized form (or forms) of
rifampicin is more potent than the parent compoundsoluble oligomers enriched in -structure.
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itself, and that rifampicin or a fragment is present in the However, if the products of fibril inhibition or disaggre-
gation are neurotoxic, then the accumulation of stablemonomers and oligomers resulting from inhibition or
disaggregation, suggesting covalent incorporation. In fibrillar deposits, such as Lewy bodies in Parkinson’s
disease, could be a marker of neurons that are relativelythe context of the minimum kinetic scheme for -synu-
clein aggregation, rifampicin and its oxidation products resistant to the neurodegenerative process. In addition,
if the end products of rifampicin inhibition/dissociationfavor the pathway leading to soluble oligomers and sta-
bilization of these species. The fact that less than stoi- of -synuclein fibrils, the soluble oligomers, are neuro-
toxic, then therapeutic treatments based on rifampicinchiometric amounts of rifampicin are required for inhibi-
tion is attributed to the formation of heterologous will not be feasible.
Whereas there is strong support that the incidence ofoligomers of rifampicin-modified and unmodified -synu-
clein. dementia is decreased in leprosy patients taking rifampi-
cin, there are conflicting accounts of whether rifampicinAn understanding of the underlying molecular mecha-
nism of rifampicin-induced inhibition and disaggrega- is effective in inhibiting formation of fibrils from A [25,
26, 45–47]. Interestingly, a leprosy genetic susceptibilitytion is complicated by the instability of rifampicin. Since
our data show that samples of rifampicin that had been locus has been mapped to a region shared by the Parkin-
son’s disease gene PARK2 [48].preincubated for 24 or 48 hr were more effective inhibi-
tors, and that much less inhibition was observed by
rifampicin under anaerobic conditions or in the presence Significance
of antioxidants, in which oxidation is prevented, it is
likely that an oxidation product is the major species We show that the antibiotic rifampicin, in substoichio-
responsible for inhibition of fibrillation. Thus, we believe metric low micromolar concentrations, inhibits -synu-
that it is a quinone form of rifampicin that is the major clein fibrillation and disaggregates existing fibrils in a
active species in the inhibition. The inhibition of -synu- concentration-dependent manner. In both inhibition
clein fibrillation by dopamine and related catechola- and disaggregation, the end product is a mixture of
mines has been reported [21, 30]. Conway et al. [21] monomer and large soluble oligomers of -synuclein
proposed that the mechanism of inhibition involved the with substantial sheet structure. The results indicate
orthoquinone derivative of dopamine forming a covalent that an oxidized form (or forms) of rifampicin is more
adduct with 5%–10% of the -synuclein. The small potent than the parent compound itself, and that rifam-
amounts of covalently modified -synuclein inhibited picin or a structural fragment is present in the mono-
fibrillation, leading to the accumulation of protofibrils. mers and oligomers resulting from inhibition or disag-
Quinones are susceptible to nucleophilic attack via gregation, suggesting covalent incorporation, most
Michael addition or imine (Schiff-base) formation by the likely by the quinone form. The data indicate that in the
lysine side chains of -synuclein, leading to covalent presence of rifampicin the aggregation of -synuclein
modification. The spectrum of -synuclein in the oligo- involves kinetic partitioning to a pathway leading to
mer stabilized by rifampicin shows evidence for such relatively stable soluble oligomers, rather than fibrils.
covalent modification, in that the absorbance spectrum These results indicate that rifampicin potentially may
of the oligomer from -synuclein plus rifampicin shows have therapeutic application for Parkinson’s disease.
the spectral signal of rifampicin or a derivative, although,
Experimental Proceduresas noted in the Results, covalent modification of the
protein was not confirmed by mass spectrometry. The
Materials
SEC HPLC data show that rifampicin or its oxidation Rifampicin and Thioflavin T (ThT) were obtained from Sigma and
products result in the formation of a slowly dissociating Fluka, respectively. All other chemicals were of analytical grade
oligomer of -synuclein. It is the presence of this stable from Fisher.
oligomer that is most likely responsible for the lack of
Synuclein Purificationfibrillation. The oligomers were also observed by EM
Human wild-type -synuclein was expressed in the E. coli BL21(DE3)and light scattering.
cell line transfected with pRK172/-synuclein WT plasmid (the kindInterestingly, although oxidized rifampicin is more ef- gift of M. Goedert, MRC Cambridge) and purified as previously de-
fective, rifampicin itself is still quite efficient in disaggre- scribed [49]. Lyophilized protein was dissolved immediately before
gating fibrils of -synuclein. Consequently, the issue of use in deionized, purified H2O, and the pH was adjusted to 10 
0.5 with 0.1 N NaOH (about 3 mM final) to solubilize any aggregatedwhether rifampicin will be oxidized or not in vivo is not
protein. After 10 min incubation at room temperature, the pH wascritical to its potential utility in treating PD. The results
readjusted to 7–8 with 0.1 N HCl. The protein concentration waswith rifampicin are very similar to those we have recently
determined by measuring the absorbance at 275 nm and using anobserved with baicalein, a flavonoid, which also inhibits
extinction coefficient of 0.40 mg	1cm2. For fibrillation assays, the
-synuclein fibrillation and disaggregates existing fibrils solution was centrifuged at 14,000 rpm for 10 min prior to starting
by stabilizing a soluble oligomer [44]. As with rifampicin, the incubation.
an oxidized quinone form is more effective in inhibition
Fibril Formationthen the parent compound, but there is little difference
-synuclein was incubated for various time periods under the follow-in disaggregation.
ing conditions. Protein concentration was kept at 1.0 mg/ml (70 M)These observations have important implications for
in 25 mM Tris-HCl and 0.1 M NaCl at pH 7.6 (fibrillation buffer).our understanding of protein deposition diseases. If fi-
Samples (0.5 ml) of protein solution in glass vials with or without
brillar -synuclein contributes to degeneration of nigral rifampin were stirred with micro-stir bars at 37C. Aliquots of 5 l
neurons, then disassembly of fibrils by rifampicin may of the reaction mixture were removed from the incubated sample
and added to 1.0 ml of 10 M ThT in fibrillation buffer, from whichreverse or slow down the progression of the disease.
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fibril formation was monitored by characteristic changes in ThT References
fluorescence. Incubations were run at least in duplicate, and all
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